Fannin Innovation Studio: Fannin Entrepreneurship Fellow

Are you contemplating a career outside academia?

 Do you want to contribute to a collaborative team environment developing novel therapeutics and medical devices?

 Would you like to assess markets for promising science/technologies with the potential to improve patients’ lives?

 Become a Fannin Entrepreneurship Fellow!

As a Fannin Fellow you will be a key member of a diverse, highly skilled team, gaining hands-on experience with drug or medical device development as you help solve problems that can change patient care.

During the two-year program, you will:

  • Learn about life sciences technology development as you contribute to a variety of projects across Fannin’s therapeutics and device portfolio
  • Complement your hands-on training with our didactic Fellow Development Program
  • Build a network of biomedical entrepreneurs, key opinion leaders, and other industry professionals
  • Attend industry relevant workshops and conferences


You need to have a passion for drug and/or medical device development and be willing to roll up your sleeves to do whatever is required in an intense but supportive startup environment. You should have a doctoral or master’s degree in life sciences, medicine, health, engineering, or related field and a record of academic success. Leadership and commercialization experience is a plus. Fannin’s collaborative workplace environment is committed to diversity, gender parity, and inclusiveness.

Position is located in Houston, TX. All applicants must be authorized to work lawfully in the United States without sponsorship for the duration of the fellowship. Compensation for fellows is based on the NIH postdoctoral fellow stipend levels.


Submit a two-page resume and a one-page statement of interest as a single PDF file to Serena Miggins at

Please put “2018 Fall Entrepreneurship Fellow Application” in the subject line of your email.

2018.08.27 _Fellowship_flyer_device_and_therapeutics

Leave A Reply:

(optional field)

No comments yet.